SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
16 references·0 citing·31 second hop
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders (2021)From psychiatry to neurology: Psychedelic…Trial of Psilocybin versus Escitalopram for Depression (2021)Trial of Psilocybin versus Es…MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021)MDMA-assisted therapy for sev…The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects (2020)The Subjective Effects of Psy…Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer (2020)Long-term follow-up of psiloc…A non-hallucinogenic psychedelic analogue with therapeutic potential (2020)A non-hallucinogenic psychede…The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act (2018)The abuse potential of medica…Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (2018)Rapid antidepressant effects …Psychedelics Promote Structural and Functional Neural Plasticity (2018)Psychedelics Promote Structur…Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms (2017)Psilocybin for treatment-resi…Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016)Rapid and sustained symptom r…Psychedelics as Medicines: An Emerging New Paradigm (2016)Psychedelics as Medicines: An…Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016)Psilocybin produces substanti…Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies (2010)Acute, subacute and long-term…Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder (2006)Safety, Tolerability, and Eff…Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance (2006)Psilocybin can occasion mysti…The pharmacology of psilocybin (2002)The pharmacology of psilocybinThe Yale-Brown Obsessive Compulsive Scale (1989)Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action (1998)World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision (2008)The neurobiology of psychedelic drugs: implications for the treatment of mood disorders (2010)The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (2017)"Mysticism and Philosophy" (1960)Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (2020)Mysticism and Philosophy (2024)Manual for the State-Trait Anxiety Inventory (1970)The Hospital Anxiety and Depression Scale (1983)Optimism, coping, and health: Assessment and implications of generalized outcome expectancies. (1985)REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019)Psychedelics (2016)Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (2016)Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function (2018)The entropic brain - revisited (2018)Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders (2020)A RATING SCALE FOR DEPRESSION (1960)Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety (2019)Posttraumatic Stress Disorder in the National Comorbidity Survey (1995)The Clinician-Administered PTSD Scale for DSM–5 (CAPS-5): Development and initial psychometric evaluation in military veterans. (2017)Adverse effects of psychedelics: From anecdotes and misinformation to systematic science (2022)MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (2023)Psychedelics reopen the social reward learning critical period (2023)Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo (2021)Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice (2021)Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial (2022)Psychedelics promote plasticity by directly binding to BDNF receptor TrkB (2023)Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder (2022)Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022)Single-Dose Psilocybin Treatment for Major Depressive Disorder (2023)
this work references cited by second hop

References

  • 2016Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial2,196 cited
  • 2016Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial1,696 cited
  • 2006Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance1,682 cited
  • 2021Trial of Psilocybin versus Escitalopram for Depression1,386 cited
  • 2018Psychedelics Promote Structural and Functional Neural Plasticity1,201 cited
  • 2021MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study996 cited
  • 2018Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial851 cited
  • 2006Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder789 cited
  • 2017Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms587 cited
  • 2020The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects538 cited
  • 2010Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies531 cited
  • 2020A non-hallucinogenic psychedelic analogue with therapeutic potential468 cited
  • 2002The pharmacology of psilocybin

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

463 cited
  • 2016Psychedelics as Medicines: An Emerging New Paradigm372 cited
  • 2020Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer359 cited
  • 2018The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act353 cited
  • Cited by

    No citing works inside the corpus for this window.